Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Absolute hypovolemia ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...

FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/ -- Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an intravenously ...

Septic shock affects more than 230,000 U.S. patients each year, but JAMA has published new advances in diagnosing and treating this clinical emergency in hopes of reducing that number. Here are three ...

Rather than providing a standardized treatment for patients with septic shock, experts argue that the treatment should be tailored based on the heterogeneity of sepsis. Septic shock is one of the most ...

sepsis-septic-shock-CA0416 Sepsis should be defined as life-threatening organ dysfunction as a response to infection. Consensus definitions for sepsis and septic shock have been revised for the first ...

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first ...

KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and ...